KRISTINE FISHER: Open Payments
NPI 1003515792 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$424 in 16 payments from 12 companies in 2025. Trend: 2023 $370 · 2024 $574 · 2025 $424
Food & beverage: $424
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $80 |
| Merck Sharp & Dohme LLC | 3 | $69 |
| JAZZ PHARMACEUTICALS INC. | 1 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Janssen Biotech, Inc. | 1 | $31 |
| Iovance Biotherapeutics, Inc. | 1 | $28 |
| PharmaEssentia USA Corporation | 1 | $28 |
| Incyte Corporation | 1 | $25 |
| Gilead Sciences, Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $23 |
Products named: KEYTRUDA, OJJAARA, ZEPZELCA, FRUZAQLA, RYBREVANT, JEMPERLI, Amtagvi, BESREMI.
Industry payments across MD — which companies pay providers there.
